Testicular germ cell tumors: pathogenesis, diagnosis and treatment (Q37813398)

23 August 2017

1 reference

title

Testicular germ cell tumors: pathogenesis, diagnosis and treatment (English)

1 reference

23 August 2017

0 references

Christian Winter

1

1 reference

PubMed ID

21116298

23 August 2017

Peter Albers

series ordinal

2

1 reference

23 August 2017

30 November 2010

1 reference

Nature Reviews Endocrinology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

1

1 reference

23 August 2017

43-53

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2010.196

23 August 2017

0 references

cites work

Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Testicular germ-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Trends in the incidence of testicular germ cell tumors in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Epidemiology of testicular cancer: an overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Persistent organochlorine pesticides and risk of testicular germ cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

The management and clinical course of testicular seminoma: 15 years' experience at a single institution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Stage I testicular seminoma: results of adjuvant irradiation and surveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Surveillance in stage I testicular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

High risk NSGCT: case for surveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Surveillance in stage I nonseminomatous germ cell tumours of the testis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Retroperitoneal lymph node dissection after chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Initial chemotherapy for stage II testicular non-seminoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tu

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Late relapse of nonseminomatous germ cell tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Late relapse of germ cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Short- and long-term morbidity after treatment for testicular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Noncancer causes of death in survivors of testicular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Fertility after chemotherapy for testicular germ cell cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Paternity following treatment for testicular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Good-risk-advanced germ cell tumors: historical perspective and current standards of care.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.196

Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients

31 March 2020

1 reference

12 December 2020

Recent developments in the pathology of germ cell tumors

1 reference

12 December 2020

Canadian consensus guidelines for the management of testicular germ cell cancer

1 reference

12 December 2020

Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres

1 reference

12 December 2020

Diagnosis of hypogonadism: clinical assessments and laboratory tests

1 reference

12 December 2020

Surveillance in stage I testicular seminoma - risk of late relapse

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2010.196

1 reference

23 August 2017

1 reference

PubMed ID

21116298